Table 1.
Patients characteristics
| All patients (n = 121) | |
|---|---|
| Age (years) | 73 ± 7.3 |
| Body weight (kg) | 81.0 ± 13.7 |
| Time since diagnosis of prostate cancer (years) | 7 ± 11 |
| Gleason score at diagnosisa | |
| < 8 | 38 (36%) |
| ≥ 8 | 69 (64%) |
| PSA at the time of PET/CT imaging (ng/ml) | 114 ± 671 |
| Prior lines of systemic treatment | |
| 2 | 8 (7%) |
| ≥ 3 | 113 (93%) |
| ≥ 4 | 78 (64%) |
| ≥ 5 | 44 (36%) |
| ≥6 | 25 (21%) |
| Sites of disease on PSMA-PET | |
| Bone | 112 (93%) |
| Lymph nodes | 97 (80%) |
| Visceralb | 43 (36%) |
| Bone + lymph nodes | 88 (73%) |
| Bone + lymph nodes + visceral | 34 (28%) |
Data are median ± standard deviation or n (%)
PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen
aData missing for 14 patients
bVisceral includes liver, lungs, and adrenal glands